HRTS241220C42000
- 0.00
- 0.000.00%
Tema GLP-1, Obesity & Cardiometabolic ETF Newsroom
With limited participants, export stocks are leading the market.
The Nikkei average continued to rise significantly, closing at 39,568.06 yen, up 437.63 yen (with an estimated Volume of 1.9 billion 60 million shares). With European and American markets closed, market participants were limited and the day started slightly lower. However, as the yen temporarily weakened to around 157 yen per dollar, export stocks such as Automobiles were actively bought, and the Nikkei average even extended its gains to 39,592.28 yen towards the end of the afternoon session. Additionally, as the final trading day for year-end settlements approached, individual tax-saving sell-offs also peaked.
Express News | Lilly's weight loss medication is now available for purchase on e-commerce platforms in China
Eli Lilly's Weight Loss Med Tirzepatide Gets Endorsement From U.K.'s NICE
Today's Pre-Market Movers and Top Ratings | TIVC, NEUE, X, and More
How Is The Market Feeling About Alnylam Pharmaceuticals?
Biggest Stock Movers Tuesday: X, CYTK, and More
The impact of rising U.S. tech stocks is limited, leading to a shift towards value stocks.
The Nikkei Average fell. It closed at 39,036.85 yen, down 124.49 yen (Volume estimated at 1.8 billion and 40 million shares). Following the rise in US stocks the previous day, buying began to lead, and shortly after the opening, it increased to 39,245.75 yen. However, with the Christmas holiday approaching, the movements of Overseas investors were sluggish, and there was no active push for higher prices. Subsequently, the focus shifted to profit-taking rebalance movements, and by the end of the first half, it dropped to 38,995.76 yen, approaching the key level of 39,000 yen.
Eli Lilly Stock Is Rising Monday: What's Going On?
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication
JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $500
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup